Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CSTA
REST API REST API
Homo sapiens
CSTA is differentially expressed in 279 experiments: 156 organism parts: lung, bone marrow, ... (154 more);, 178 disease states: normal, glioblastoma, ... (176 more);, 119 cell types 414 cell lines 36 compound treatments and 60 other conditions.
Synonyms STFA, STF1
Orthologs Gm5483 (Mus musculus)   Gm1975 (Mus musculus)   CSTA (Bos taurus)   Gm10092 (Mus musculus)   CSTA (Gallus gallus)   Stfa3 (Mus musculus)   Stfa2l1 (Mus musculus)   si:ch211-161h7.6 (Danio rerio)   Gm5416 (Mus musculus)   zgc:56530 (Danio rerio)   2010005H15Rik (Mus musculus)   Csta (Mus musculus)   zgc:153129 (Danio rerio)   Stfa2 (Mus musculus)   BC100530 (Mus musculus)   Stfa1 (Mus musculus)   Gm4758 (Mus musculus)   F1M861_RAT (Rattus norvegicus)   LOC684525 (Rattus norvegicus)   LOC100364985 (Rattus norvegicus)   Csta (Rattus norvegicus)   Stfa3 (Rattus norvegicus)   Stfa2l2 (Rattus norvegicus)   LOC684499 (Rattus norvegicus)   Stfa2l1 (Rattus norvegicus)   Stfa3l1 (Rattus norvegicus)   Gm5689 (Mus musculus)   ENSXETG00000032236 (Xenopus laevis)   CSTA (Canis familiaris)   (Compare orthologs)
InterPro Term Prot_inh_cystat, Prot_inh_stefinA
Gene Ontology Term cytoplasm, intracellular, structural molecule activity, nucleus, cysteine-type endopeptidase inhibitor activity, protein binding, bridging, peptide cross-linking, protease binding, negative regulation of peptidase activity, cornified envelope, keratinocyte differentiation
UniProt Accession C9J0E4, P01040, Q6IB90
Search EB-eye ENSG00000121552
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-803, E-GEOD-6573, E-GEOD-3526, E-MTAB-62, ... (26 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (42 experiments)

Factor Value U/D Experiments
MCF-7
4
E-GEOD-5823, E-GEOD-20081, E-GEOD-19639, E-GEOD-3529
Jurkat
3
E-GEOD-1880, E-MEXP-2197, E-MTAB-62
HL-60
3
E-GEOD-5258, E-MTAB-37, E-GEOD-24147
SW480
3
E-GEOD-18005, E-MEXP-1014, E-MTAB-37
A549
2
E-GEOD-3202, E-GEOD-6013
HCC1937
2
E-MTAB-62, E-MTAB-37
408 more value(s).


Cell type

studied in E-GEOD-500, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, E-TABM-34, ... (53 experiments)

Factor Value U/D Experiments
CD8+ T cell
3
E-AFMX-5, E-GEOD-19069, E-GEOD-6740
plasma cell
2
E-MEXP-2360, E-GEOD-6691
CD33+ myeloid
2
E-AFMX-5, E-TABM-145
macrophage
2
E-GEOD-22373, E-GEOD-3982
mononuclear cell
2
E-GEOD-6053, E-GEOD-7307
monocyte
2
3
E-GEOD-22373, E-MEXP-2019, E-GEOD-11755, E-GEOD-7307, E-MEXP-583 ... (5 experiments)
113 more value(s).


Disease state

studied in E-GEOD-1615, E-GEOD-3307, E-GEOD-2466, E-GEOD-16363, E-MTAB-62, ... (64 experiments)

Factor Value U/D Experiments
glioblastoma
1
4
E-GEOD-4290, E-GEOD-4412, E-MTAB-62, E-MEXP-567, E-GEOD-6014 ... (5 experiments)
control
2
E-GEOD-16363, E-GEOD-8121
Huntington's disease
2
E-AFMX-6, E-GEOD-3790
AIDS-KS, HIV+, nodular (late) stage
2
E-MEXP-66, E-MTAB-62
acute promyelocytic leukemia
2
E-GEOD-995, E-MTAB-62
cervical carcinoma
2
E-MTAB-62, E-MTAB-37
172 more value(s).


Compound treatment

studied in E-GEOD-4668, E-GEOD-6907, E-TABM-782, E-TABM-868, E-GEOD-5099, ... (24 experiments)

Factor Value U/D Experiments
lipopolysaccharide
3
E-TABM-868, E-MEXP-1958, E-GEOD-3982
control
2
E-GEOD-3284, E-GEOD-995
actinomycin D
1
E-GEOD-6400
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
non-targeting
1
E-MEXP-2218
endotoxin
1
E-GEOD-2322
30 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519


Biosource provider
studied in E-GEOD-14359

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Clinical history
studied in E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, E-GEOD-21589, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-1140, E-GEOD-994, E-MEXP-1251, ... (9 experiments)

Clinical treatment
studied in E-GEOD-2171, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-5999, E-GEOD-20033, E-MTAB-62

Disease staging
studied in E-GEOD-19743, E-TABM-147

Environmental stress
studied in E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Genetic modification
studied in E-MTAB-73, E-GEOD-4025, E-GEOD-7578, E-MTAB-108, E-MEXP-2340, ... (6 experiments)

Genotype
studied in E-GEOD-1045, E-GEOD-2466, E-GEOD-17476, E-GEOD-22593, E-TABM-868, ... (13 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-GEOD-5681, E-GEOD-12773, E-TABM-127, E-GEOD-22278, ... (8 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-16194

Individual
studied in E-TABM-325, E-MTAB-197, E-TABM-740, E-MEXP-2069, E-GEOD-1926, ... (34 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12108

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-22056

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Performer
studied in E-LGCL-5

Phase
studied in E-GEOD-4888

Phenotype
studied in E-GEOD-21750, E-GEOD-1657, E-GEOD-17636, E-GEOD-2487, E-MEXP-1403 ... (5 experiments)

Population
studied in E-GEOD-4922

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343 ... (5 experiments)

Replicate
studied in E-GEOD-10797, E-GEOD-18791

RNAi
studied in E-MEXP-1857

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

Sample type
studied in E-TABM-783

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-17400

Sex
studied in E-GEOD-1643, E-GEOD-19069, E-GEOD-2466, E-GEOD-7307, E-GEOD-16363 ... (5 experiments)

Stimulation
studied in E-GEOD-4883, E-GEOD-20114, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Treatment
studied in E-MEXP-973, E-GEOD-19246, E-GEOD-19815, E-GEOD-15799, E-GEOD-12198 ... (5 experiments)

Tumor grading
studied in E-GEOD-4290, E-TABM-43, E-GEOD-1561, E-GEOD-4922

Processing time: 0.389 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM